OBJECTIVE — We determined the relationships between glycemia at randomization, con-current antidiabetic therapy, and change in A1C and fasting plasma glucose (FPG) in patients with diabetes receiving standard treatment for diabetes and randomized to ranolazine or placebo within the MERLIN-TIMI-36 (MERLIN) study. Ranolazine is a novel first-in-class drug approved for treating angina pectoris. RESEARCH DESIGN ANDMETHODS — Randomization and 4-month glycemic and antidiabetes drug usage data from MERLIN were analyzed using Spotfire and SAS version 9.1 software. RESULTS — In patients with diabetes and A1C of 8–10 % at randomization (n 171), there was an absolute A1C reduction in the ranolazine group of 1.2 % (95 % CI 1.4 to 1.0), and the placebo...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139109/1/jah32151.pdfhttps://deepblue....
ObjectivesThis study examined the hypothesis that the improvement in myocardial blood flow (MBF) wit...
Background: Previous studies have suggested that blockade of the renin-angiotensin system may preven...
Background—Ranolazine is a novel antianginal shown in an exploratory analysis in patients with diabe...
Background: Diabetes mellitus is the fifth leading cause of death worldwide and is one of the common...
Background. Ranolazine is a second-line drug for the management of chronic coronary syndromes (CCS)....
ObjectivesThis study sought to examine the efficacy of ranolazine versus placebo on weekly angina fr...
Aims The anti-anginal efficacy and safety of ranolazine in diabetic and non-diabetic patients includ...
Pawan D Patel, Rohit R AroraDepartment of Cardiology, Chicago Medical School, North Chicago, IL, USA...
Background: Type 2 diabetes mellitus is one of the most common metabolic disorders at present with i...
Prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. Nowadays over 360 million peo...
Ranolazine is a new antianginal agent believed to reduce oxygen demand through its metabolic action ...
Ischemic heart disease is a significant public health problem with high mortality and morbidity. Ext...
Type 2 diabetes mellitus (T2DM) is a risk factor for cognitive impairment. Ranolazine, an anti-ische...
The author reflects on the meaningful difference between statistical and clinical significance
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139109/1/jah32151.pdfhttps://deepblue....
ObjectivesThis study examined the hypothesis that the improvement in myocardial blood flow (MBF) wit...
Background: Previous studies have suggested that blockade of the renin-angiotensin system may preven...
Background—Ranolazine is a novel antianginal shown in an exploratory analysis in patients with diabe...
Background: Diabetes mellitus is the fifth leading cause of death worldwide and is one of the common...
Background. Ranolazine is a second-line drug for the management of chronic coronary syndromes (CCS)....
ObjectivesThis study sought to examine the efficacy of ranolazine versus placebo on weekly angina fr...
Aims The anti-anginal efficacy and safety of ranolazine in diabetic and non-diabetic patients includ...
Pawan D Patel, Rohit R AroraDepartment of Cardiology, Chicago Medical School, North Chicago, IL, USA...
Background: Type 2 diabetes mellitus is one of the most common metabolic disorders at present with i...
Prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. Nowadays over 360 million peo...
Ranolazine is a new antianginal agent believed to reduce oxygen demand through its metabolic action ...
Ischemic heart disease is a significant public health problem with high mortality and morbidity. Ext...
Type 2 diabetes mellitus (T2DM) is a risk factor for cognitive impairment. Ranolazine, an anti-ische...
The author reflects on the meaningful difference between statistical and clinical significance
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139109/1/jah32151.pdfhttps://deepblue....
ObjectivesThis study examined the hypothesis that the improvement in myocardial blood flow (MBF) wit...
Background: Previous studies have suggested that blockade of the renin-angiotensin system may preven...